Přihlásit se Zaregistrujte se zdarma

Návratnost kapitálu společnosti Cue Biopharma Inc

Jaká je hodnota metriky Návratnost kapitálu společnosti Cue Biopharma Inc?

Hodnota metriky Návratnost kapitálu společnosti Cue Biopharma Inc je -176.68%

Jaká je definice metriky Návratnost kapitálu?



Return on capital employed (ROCE) je finanční ukazatel, který měří rentabilitu společnosti a efektivitu společnosti ve využívání vlastního kapitálu.

Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.

ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.

Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.

Návratnost kapitálu společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Cue Biopharma Inc

Čemu se věnuje společnost Cue Biopharma Inc?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Firmy s metrikou návratnost kapitálu podobnou společnosti Cue Biopharma Inc